Pharvaris N.V. announced the departure of Anne Marie de Jonge Schuermans, Ph.D., non-executive Director, from the Board of Directors, effective July 1, 2023. Dr. de Jonge Schuermans will be replaced by Robert Glassman, M.D. as a member of the Audit Committee and Viviane Monges as a member on the Nomination & Corporate Governance Committee. The departure of Dr. de Jonge Schuermans was not as a result of a disagreement with the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.82 USD | +0.93% | -9.82% | -43.07% |
Jun. 04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.07% | 843M | |
+48.28% | 57.87B | |
+41.65% | 40.25B | |
-7.17% | 39.94B | |
-5.96% | 28.54B | |
+12.19% | 26.4B | |
-20.08% | 19.33B | |
+29.90% | 12.4B | |
-0.79% | 12.23B | |
+24.68% | 12.2B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris N.V. Announces Board Changes